The Sinusitis Treatment Market is projected to register a CAGR of 6.4% during the forecast period.
The COVID-19 pandemic had an effect on the market. The outbreak of COVID-19 infections in the global population was expected to be associated with sinusitis infections in the infected patients, thereby driving the growth of the market. The article published in the National Library of Medicine in May 2021 mentioned that patients diagnosed with acute invasive fungal rhino-sinusitis associated with recent COVID-19 infection and treated at Manusora University were analyzed. All patients had a definite diagnosis of COVID-19 by PCR and CT studies with post-COVID invasive fungal sinusitis. As a result, during the pandemic, the Sinusitis Treatment Market is expected to grow because of the increased demand for effective treatment.
Sinusitis can be acute or chronic, with different germs such as bacteria and viruses blocking the nasal cavities or filling them with fluid if not treated. Sinusitis can progress to complications such as a brain abscess and meningitis if it is not treated or detected. Blood tests, ciliary function tests, nasal cytology & allergy testing, sinus CT scans, and sinus MRIs are all available for diagnostic purposes. Antibiotics are the first line of treatments followed by decongestants and surgery at a severe stage.
Market growth can be attributable to a variety of factors, including the rising prevalence rate of sinusitis, increased demand for diagnostic tests and antibiotics, and technological advancements in sinusitis surgery.
Additionally, the growing use of medical devices for disease diagnosis and treatment, as well as the use of various medications for treatment such as nasal sprays, nasal corticosteroids, and decongestants, are key parameters in the unprecedented growth of the sinusitis treatment market during the forecast period. According to the article titled ' Chronic Sinusitis' published in June 2021, corticosteroids are frequently utilized in the treatment of people with chronic sinusitis. Large-volume corticosteroid irrigation helps patients with chronic sinusitis after sinus surgery.
The primary strategies of the companies in this market are new product launching to find out better solution for sinusitis treatment. For instance, according to Clinic Barcelona 2021, monoclonal antibodies are effective form of precision medicine in sinusitis with polyps and different clinical trials have been carried out with the drugs omalizumab (IgE), mepolizumab (IL-5), reslizumab (IL-5) and dupilumab (IL4 α) to know there effectiveness. In May 2020, Nasus Medical, a startup born out of Stanford Biodesign and now a Fogarty Institute company, is working on a solution for better intra-nasal drug delivery. When the first signs of chronic sinusitis arise, their novel device promises to allow patients to treat themselves at home.
Thus the above-mentioned factors are exected to drive the growth of the market during the forecast period.
Similarly, the article published in the National Library of Medicine in February 2021 mentioned that the prevalence rate of chronic sinusitis is around 10.9% in Europe, 13% in the United States, 6.95% in South Korea, and 8% in China, which may lead to increased demand of antibiotics. For a better treatment of acute sinusitis in adults, there is a need to rethink the current approach to treatment. The development of new therapies and drugs would require lots of time, effort, scientific research, and capital. As a result, players are stepping up their R&D efforts to provide better alternative solutions for treating patients suffering from sinusitis.
As per the article titled ' Sinusitis' published in May 2022, sinusitis is one of the most common reasons for clinical visits in the United States and leads to 73 million restricted-activity days over one year. In addition, the health awareness and active presence of significant players are expected to fuel the market growth in this region. For instance, in March 2021 the United States Food and Drug Administration expanded the use of ClearUp sinus Pain relief treatment to include indications for treating congestion.
Clinical trials are another factor in market growth. For instance, in July 2022, St. Paul's Hospital, Canada launched a randomized, double-blind, placebo-controlled trial of 80 subjects to test whether a sinus power wash plus sinonasal microbiota transfer (SNMT) improves clinical outcomes in chronic sinusitis (CRS) patients within 45 days compared to a sinus power wash and sham SNMT. The investigators investigated the safety profile of SNMT to determine if SNMT-related CRS symptom improvement lasts up to 6 months. Finally, the investigators investigated how SNMT contributes to CRS recovery, by tracking changes in the sinus microbiota and inflammation pre-and post-treatment. Thus, such clinical trials are expected to provide better treatment in the region which is expected to increase the market growth.
Thus, the increasing prevalence of sinusitis, awareness campaigns, and clinical trials are expected to increase market growth over the forecast period.
This product will be delivered within 2 business days.
The COVID-19 pandemic had an effect on the market. The outbreak of COVID-19 infections in the global population was expected to be associated with sinusitis infections in the infected patients, thereby driving the growth of the market. The article published in the National Library of Medicine in May 2021 mentioned that patients diagnosed with acute invasive fungal rhino-sinusitis associated with recent COVID-19 infection and treated at Manusora University were analyzed. All patients had a definite diagnosis of COVID-19 by PCR and CT studies with post-COVID invasive fungal sinusitis. As a result, during the pandemic, the Sinusitis Treatment Market is expected to grow because of the increased demand for effective treatment.
Sinusitis can be acute or chronic, with different germs such as bacteria and viruses blocking the nasal cavities or filling them with fluid if not treated. Sinusitis can progress to complications such as a brain abscess and meningitis if it is not treated or detected. Blood tests, ciliary function tests, nasal cytology & allergy testing, sinus CT scans, and sinus MRIs are all available for diagnostic purposes. Antibiotics are the first line of treatments followed by decongestants and surgery at a severe stage.
Market growth can be attributable to a variety of factors, including the rising prevalence rate of sinusitis, increased demand for diagnostic tests and antibiotics, and technological advancements in sinusitis surgery.
Additionally, the growing use of medical devices for disease diagnosis and treatment, as well as the use of various medications for treatment such as nasal sprays, nasal corticosteroids, and decongestants, are key parameters in the unprecedented growth of the sinusitis treatment market during the forecast period. According to the article titled ' Chronic Sinusitis' published in June 2021, corticosteroids are frequently utilized in the treatment of people with chronic sinusitis. Large-volume corticosteroid irrigation helps patients with chronic sinusitis after sinus surgery.
The primary strategies of the companies in this market are new product launching to find out better solution for sinusitis treatment. For instance, according to Clinic Barcelona 2021, monoclonal antibodies are effective form of precision medicine in sinusitis with polyps and different clinical trials have been carried out with the drugs omalizumab (IgE), mepolizumab (IL-5), reslizumab (IL-5) and dupilumab (IL4 α) to know there effectiveness. In May 2020, Nasus Medical, a startup born out of Stanford Biodesign and now a Fogarty Institute company, is working on a solution for better intra-nasal drug delivery. When the first signs of chronic sinusitis arise, their novel device promises to allow patients to treat themselves at home.
Thus the above-mentioned factors are exected to drive the growth of the market during the forecast period.
Sinusitis Treatment Market Trends
Antibiotics Segment is Anticipated to Show Considerable Growth During the Forecast Period
Analgesics, Antihistamines, Corticosteroids, Antibiotics, and Surgery are among the treatments available in the global sinusitis treatment market. Antibiotics are recommended for bacterial sinusitis involving the frontal, sphenoid, or ethmoid sinuses, as this type of sinusitis can produce more serious problems. Antibiotics like Penicillins, cephalosporins, and macrolides have been recommended for a long time. According to the article published in the National Library of Medicine in August 2022 Antibiotics may be prescribed when symptoms of a sinus infection warrant such treatment. Common antibiotics for sinus infection include Augmentin, Zithromax, Levaquin, Septra, and Amoxil.Similarly, the article published in the National Library of Medicine in February 2021 mentioned that the prevalence rate of chronic sinusitis is around 10.9% in Europe, 13% in the United States, 6.95% in South Korea, and 8% in China, which may lead to increased demand of antibiotics. For a better treatment of acute sinusitis in adults, there is a need to rethink the current approach to treatment. The development of new therapies and drugs would require lots of time, effort, scientific research, and capital. As a result, players are stepping up their R&D efforts to provide better alternative solutions for treating patients suffering from sinusitis.
North America is Expected to have Significant Market Share in the Sinusitis Treatment Market Over the Forecast Period
North America accounted for a significant share of the sinusitis treatment market because of the high prevalence rate of sinusitis.As per the article titled ' Sinusitis' published in May 2022, sinusitis is one of the most common reasons for clinical visits in the United States and leads to 73 million restricted-activity days over one year. In addition, the health awareness and active presence of significant players are expected to fuel the market growth in this region. For instance, in March 2021 the United States Food and Drug Administration expanded the use of ClearUp sinus Pain relief treatment to include indications for treating congestion.
Clinical trials are another factor in market growth. For instance, in July 2022, St. Paul's Hospital, Canada launched a randomized, double-blind, placebo-controlled trial of 80 subjects to test whether a sinus power wash plus sinonasal microbiota transfer (SNMT) improves clinical outcomes in chronic sinusitis (CRS) patients within 45 days compared to a sinus power wash and sham SNMT. The investigators investigated the safety profile of SNMT to determine if SNMT-related CRS symptom improvement lasts up to 6 months. Finally, the investigators investigated how SNMT contributes to CRS recovery, by tracking changes in the sinus microbiota and inflammation pre-and post-treatment. Thus, such clinical trials are expected to provide better treatment in the region which is expected to increase the market growth.
Thus, the increasing prevalence of sinusitis, awareness campaigns, and clinical trials are expected to increase market growth over the forecast period.
Sinusitis Treatment Market Competitor Analysis
The Sinusitis Treatment Market is fragmented. Major companies in the Sinusitis Treatment market are Olympus Corporation, Medtronic plc, Stryker, Cipla Ltd., Dr. Reddy’s Laboratories Ltd, Intersect ENT, Inc., Sanofi SA, and Aurobindo Pharma among others.Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Olympus Corporation
- Medtronic plc
- Stryker Corporation
- Cipla Ltd.
- Dr. Reddy's Laboratories Ltd
- Sanofi SA
- Aurobindo Pharma
- Smith & Nephew PLC
- Novartis AG
- GlaxoSmithKline PLC
- Teva Pharmaceutical Industries Ltd
- Bayer AG
Methodology
LOADING...
